BioNTech Net Income From Continuing Ops from 2010 to 2024

BNTX Stock  USD 114.22  6.16  5.12%   
BioNTech Net Income From Continuing Ops yearly trend continues to be fairly stable with very little volatility. Net Income From Continuing Ops will likely drop to about 883.8 M in 2024. During the period from 2010 to 2024, BioNTech Net Income From Continuing Ops regression line of annual values had r-squared of  0.22 and arithmetic mean of  1,376,076,600. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2018-06-30
Previous Quarter
-807.8 M
Current Value
198.1 M
Quarterly Volatility
1.3 B
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of BioNTech SE over the last few years. It is BioNTech's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

BioNTech Net Income From Continuing Ops Regression Statistics

Arithmetic Mean1,376,076,600
Geometric Mean199,368,060
Coefficient Of Variation251.95
Mean Deviation2,263,299,573
Median(85,950,000)
Standard Deviation3,466,986,686
Sample Variance12019996.7T
Range10.5B
R-Value0.47
Mean Square Error10077627.1T
R-Squared0.22
Significance0.08
Slope364,842,439
Total Sum of Squares168279953.5T

BioNTech Net Income From Continuing Ops History

2024883.8 M
2023930.3 M
20229.4 B
202110.3 B
202015.2 M
2019-179.2 M
2018-48.3 M

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income From Continuing Ops930.3 M883.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.